Biotech claims for safer stem cells

Written byAndrea Gawrylewski

| 1 min read

A California biotech announced at the Stem Cell Summit in New York City on Tuesday that they have successfully reprogrammed human skin, kidney, and retina cells to a stem-cell-like state without using potentially cancer-causing retroviruses. But experts say their claims are impossible to evaluate since the work has not been peer-reviewed. The company researchers did not say these new cells produced teratomas -- the sign that cells are truly pluripotent. The company, PrimeGen Biotech based in Irvine, Ca., said it used carbon-based particles coated with DNA coding for the four transcription factors Oct3/4, SOX2, c-Myc, and Klf4, the New Scientist linkurl:reported.;http://www.newscientist.com/article/dn13384-stem-cell-breakthrough-may-reduce-cancer-risk.html These are the same factors Shinya Yamanaka used with retroviruses to reprogram skin cells into stem cell-like cells linkurl:last November.;http://www.the-scientist.com/blog/display/53873/ In a statement regarding Yamanaka's paper, linkurl:Douglas Melton,;http://www.hhmi.org/research/investigators/melton_bio.html stem cell researcher at Harvard University, said that "retroviruses are a real limitation to stem cell reprogramming" because they can disrupt other genes required for normal cell function. PrimeGen said in an accompanying linkurl:press release;http://www.primegenbiotech.com/news/PR014_(2008-02-26).pdf that they are looking for sponsorship and help in developing their cell lines. But some researchers are skeptical about the company's findings. Until the results go through the peer review process they will be hard to evaluate, linkurl:James Thomson,;http://ink.primate.wisc.edu/~thomson/jamie.html at the University of Wisconsin, Madison, whose group also reported reprogrammed stem cells last November, told linkurl:Forbes.;http://www.forbes.com/business/2008/02/27/biotech-research-cells-biz-cx_mh_0227stem.html One independent researcher who has tested the new cells, linkurl:Denis Clegg;http://www.lifesci.ucsb.edu/mcdb/faculty/clegg/index.html at the University of California, Santa Barbra, told Forbes they behave like embryonic stem cells, but expressed surprise at the company's early announcement.

Biotech claims for safer stem cells

The Scientist ARCHIVES

Become a Member of

Meet the Author

Andrea Gawrylewski

Related Research Resources

What Is the Amniotic Fluid Composed of?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Skip the Wait for Protein Stability Data with Aunty

An Automated DNA-to-Data Framework for Production-Scale Sequencing

Exploring Cellular Organization with Spatial Proteomics

Organoid Origins and How to Grow Them

Products

Product News

BRANDTECH Scientific Introduces the Transferpette® pro Micropipette: A New Twist on Comfort and Control

Biotium Launches GlycoLiner™ Cell Surface Glycoprotein Labeling Kits for Rapid and Selective Cell Surface Imaging

Thermo Scientific X and S Series General Purpose Centrifuges

VANTAstar Flexible microplate reader with simplified workflows